Claryx Raises $3.5 Million in Pre-Seed Funding
Claryx, a startup based in New York City, has successfully raised $3.5 million in a pre-seed funding round. The investment was led by Outlander, with participation from several other notable investors including Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford, and Precursor.
Innovating Hospital Infection Control
Claryx is developing a system designed to function as a "hospital immune system." Its technology aims to detect infections within hospital environments, trace their spread, recommend appropriate responses, and confirm their elimination. This comprehensive approach to infection management could significantly enhance patient safety and operational efficiency in healthcare settings.
Founders' Vision
The company was founded by brothers Dirk Hackenberger, who serves as the Chief Scientific Officer, and Kurt Hackenberger, the CEO. Their combined expertise is driving the development of Claryx's innovative solutions. "Our goal is to transform how hospitals manage infections, ensuring safer environments for patients and healthcare workers," said Kurt Hackenberger.
Strategic Use of Funds
The newly acquired funds will be utilized to accelerate the development of Claryx's technology. This includes expanding the team with key hires and further advancing the platform's capabilities. By focusing on these areas, Claryx aims to bring its infection control solutions to market more rapidly, addressing a critical need in the healthcare industry.
Looking Ahead
With the support of its investors, Claryx is well-positioned to make significant strides in the field of hospital infection control. The company’s innovative approach promises to improve the detection and management of infections, ultimately contributing to better health outcomes in hospitals across the globe.